The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

• Ngā kaituhi matua: Hélène Haguet (Author), Céline Bouvy (Author), Anne-Sophie Delvigne (Author), Elise Modaffari (Author), Adeline Wannez (Author), Pierre Sonveaux (Author), Jean-Michel Dogné (Author), Jonathan Douxfils (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2020-07-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs, dasatinib, nilotinib, and ponatinib, inc...